75 results
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
6 Nov 19
Coherus BioSciences Reports Corporate Highlights and Third Quarter 2019 Financial Results
4:38pm
biosimilar-specific strategy of offering a robust value proposition across all key customer segments including ample product supply.
Achieve 2019 exit unit … strategy of offering a robust value proposition across all key customer segments, including ample product supply; Coherus’ ability to achieve 2019
8-K/A
EX-99.1
CHRS
Coherus Biosciences Inc
6 Nov 23
Report of Independent Registered Public Accounting Firm
6:07am
, collaboration arrangements and financial instruments.
In accordance with ASC Topic 606, the Company recognizes revenue when its customer obtains control … five steps:
identify the contract(s) with a customer;
ii.
identify the performance obligations in the contract;
iii.
determine the transaction price
8-K
EX-99.1
smdbu8f2
5 Nov 20
Coherus BioSciences Reports Third Quarter 2020 Financial Results
4:07pm
8-K
EX-99.1
nmf8xw ue6
6 Aug 20
Coherus BioSciences Reports Second Quarter 2020 Financial Results
4:07pm
8-K
EX-99.1
a9litp0scorisd98ynpt
7 May 20
Coherus BioSciences Reports First Quarter 2020 Financial Results
4:02pm
DRS/A
EX-10
jtpuj4hb
5 Aug 14
Draft registration statement (amended)
12:00am
8-K
EX-99.1
gnb82c nz
9 May 24
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
4:17pm
8-K
EX-99.1
6lfqch2
27 Feb 20
Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results
4:16pm
8-K
EX-99.1
3p65mnjt5r
24 Feb 21
Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results
4:05pm
DRS/A
EX-10
54jsnyob6wpip
5 Aug 14
Draft registration statement (amended)
12:00am